Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study of XOMA 358, with Optional Dose Escalation, in Patients with Congenital Hyperinsulinism

Trial Profile

An Open-Label Study of XOMA 358, with Optional Dose Escalation, in Patients with Congenital Hyperinsulinism

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RZ 358 (Primary)
  • Indications Hyperinsulinaemia; Hypoglycaemia
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors XOMA
  • Most Recent Events

    • 01 Jun 2020 Results published in Rezolute Media Release
    • 01 Jun 2020 According to a Rezolute media release, results from this trial were present at the Pediatric Endocrine Society (PES) 2020 Annual Meeting, held virtually
    • 04 Apr 2017 Results assessing activity of Xoma-358, following short-term administration to congenital hyperinsulinism patients (X358602 and X358605 Congenital Hyperinsulinism studies), presented at The 99th Annual Meeting of the Endocrine Society.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top